Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27608746 | 1.00 | KIF11 (0.78) | KIF11POLBKMT2ATDP1GSR | |
| SCHEMBL4399790 | 0.88 | KIF11 (1.00) | KIF11 | |
| SCHEMBL27590560 | 0.88 | KIF11 (1.00) | KIF11 | |
| SCHEMBL34261 | 0.81 | KIF11 (0.56) | KIF11 | |
| SCHEMBL27259404 | 0.80 | KIF11 (0.55) | KIF11POLBKMT2ATDP1GSR | |
| SCHEMBL27269884 | 0.80 | KIF11 (0.55) | KIF11POLBKMT2ATDP1GSR | |
| SCHEMBL2835140 | 0.79 | KIF11 (0.53) | KIF11 | |
| SCHEMBL8170449 | 0.78 | KIF11 (0.61) | KIF11 | |
| SCHEMBL8346825 | 0.78 | KIF11 (0.60) | KIF11 | |
| SCHEMBL29053902 | 0.77 | KIF11 (0.68) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632951-B2 | Inhibitors of integrin ανβ6 | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-12-15 | — | — | US | disclosed |
| EP-1377540-B1 | INHIBITORS OF INTEGRIN ALPHA-V-BETA-6 | MERCK PATENT GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| CN-1582271-A | Inhibitors of integrin alpha v beta 6 | MERCK PATENT GMBH (DE) | 2005-02-16 | — | — | CN | disclosed |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1377540-A1 | INHIBITORS OF INTEGRIN AvB6 | MERCK PATENT GmbH (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074730-A1 | INHIBITORS OF INTEGRIN αvβ¿6? | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | ITGB6, ITGB1, ITGA1 | KIF11 4238/4885POLB 3477/4885KMT2A 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.